<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24267160</article-id>
      <article-id pub-id-type="pmc">4222084</article-id>
      <article-id pub-id-type="publisher-id">1756-0500-6-484</article-id>
      <article-id pub-id-type="doi">10.1186/1756-0500-6-484</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Koie</surname>
            <given-names>Takuya</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>goodwin@cc.hirosaki-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A2">
          <name>
            <surname>Ohyama</surname>
            <given-names>Chikara</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>coyama@cc.hirosaki-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Okamoto</surname>
            <given-names>Akiko</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>akikaito630@yahoo.co.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Hayato</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ha-yama@cc.hirosaki-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Imai</surname>
            <given-names>Atsushi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>tsushi.imai@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Hatakeyama</surname>
            <given-names>Shingo</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>shingorilla2@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Yoneyama</surname>
            <given-names>Takahiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>uroyone@cc.hirosaki-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Hashimoto</surname>
            <given-names>Yasuhiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>y-hashi@cc.hirosaki-u.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki 036-8562, Japan</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <volume>6</volume>
      <fpage>484</fpage>
      <lpage>484</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Koie et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Koie et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1756-0500/6/484"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Targeted therapy with tyrosine kinase inhibitors has been shown to reduce tumor volumes and prolong the survival of patients with metastatic renal cell carcinoma. Tyrosine kinase inhibitors, particularly sunitinib, have recently been used in neoadjuvant and presurgical settings. Axitinib is a promising second-line therapy option for advanced or metastatic renal cell carcinoma. Herein, we report a patient with advanced renal cell carcinoma who received presurgical treatment with axitinib.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 73-year-old man was transported by ambulance to a community hospital with chief complaints of high fever and a gait disorder. Computed tomography screening revealed a hypervascular tumor (size, 9&#x2009;&#xD7;&#x2009;8.5&#xA0;cm) in the lower pole of the left kidney. Upon admission to our hospital, his general condition was poor and his performance status was judged as 3, based on the Eastern Cooperative Oncology Group performance status criteria. After biopsy for the renal tumor, he received 5&#xA0;mg of axitinib twice daily for 3&#xA0;months. No serious adverse events were reported during this treatment. The tumor diameter shrank by 56%. Left radical nephrectomy was performed, and there were no intraoperative or postoperative complications. Pathological examination indicated a pT3aN0M0, Furman grade 3, clear cell renal cell carcinoma with necrosis, hyaline degeneration, and hemosiderosis. The patient was asymptomatic and disease-free at 1&#xA0;year post-diagnosis.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This case study demonstrate that presurgical therapy with axitinib is feasible and might have several potential advantages for patients with advanced renal cell carcinoma.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Clear cell carcinoma</kwd>
        <kwd>Axitinib</kwd>
        <kwd>Presurgical therapy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Targeted therapy with tyrosine kinase inhibitors (TKIs) has been shown to reduce primary or metastatic tumor volumes and prolong the survival of patients with metastatic renal cell carcinoma (RCC) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. TKIs, particularly sunitinib, have recently been used in neoadjuvant or presurgical settings to facilitate surgery by reducing tumor sizes [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. The potential benefits of neoadjuvant or presurgical therapy include local tumor downstaging, elimination of micrometastatic disease, and diminution of postoperative metastatic progression.</p>
      <p>However, targeted therapy with TKIs has elicited some concerns regarding complications. The commonly recorded grade 3/4 clinical toxicities associated with sunitinib were gastrointestinal disorders including diarrhea or anorexia, and hematotoxicity including neutropenia or thrombocytopenia [<xref ref-type="bibr" rid="B1">1</xref>]. Targeted therapy regimens should be less toxic to prevent any treatment-related delays between neoadjuvant therapy and surgery and to achieve better oncologic outcomes in a neoadjuvant setting.</p>
      <p>Axitinib is a promising second-line therapy option for advanced or metastatic RCC [<xref ref-type="bibr" rid="B4">4</xref>]. In Japanese patients with metastatic RCC, adverse events with sunitinib was severer than the Caucasian population [<xref ref-type="bibr" rid="B5">5</xref>]. Additionally, this agent has shown anti-tumor activity and has an acceptable safety profile [<xref ref-type="bibr" rid="B6">6</xref>]. We designed a phase II single-arm trial to evaluate safety and effectiveness of presurgical treatment of advanced RCC with axitinib. This patient was enrolled this trial. Herein, we report a patient with advanced RCC who received presurgical treatment with axitinib. The patient was informed about the treatment protocol and provided written informed consent. The study protocol and informed consent documents were reviewed and approved by the Hirosaki University Institutional Review Board.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 73-year-old man was transported by ambulance to a community hospital with chief complaints of high fever and a gait disorder. Laboratory evaluations revealed the following findings: hemoglobin, 7.0&#xA0;g/dL (normal range, 13.5-17.5&#xA0;g/dL); creatine phosphokinase, 572&#xA0;IU/L (normal range, 60-270&#xA0;IU/L); free blood sugar, 226&#xA0;mg/dL (normal range, 70-109&#xA0;mg/dL); and C-reactive protein, 14.0&#xA0;mg/dL (normal range, &lt;0.3&#xA0;mg/dL). Computed tomography (CT) screening revealed a hypervascular tumor (size, 9&#x2009;&#xD7;&#x2009;8.5&#xA0;cm) in the lower pole of the left kidney (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>). The tumor was clinically diagnosed as a left RCC with a classification of cT2aN0M0, according to the tumor-node-metastasis system [<xref ref-type="bibr" rid="B7">7</xref>]. The patient was transferred to our hospital for surgical treatment.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Abdominal enhanced computed tomography (CT) before axitinib treatment.</bold> (coronal section) Abdominal CT shows a hypervascular tumor (size, 9&#x2009;&#xD7;&#x2009;8.5&#xA0;cm) in the lower pole of the left kidney.</p>
        </caption>
        <graphic xlink:href="1756-0500-6-484-1"/>
      </fig>
      <p>Upon admission to our hospital, the patient&#x2019;s general condition was poor and his performance status (PS) was judged as 3, based on the Eastern Cooperative Oncology Group performance status criteria. Laboratory evaluations revealed the following findings: hemoglobin, 6.8&#xA0;g/dL; adjusted calcium, 12.7&#xA0;mg/dL (normal range, 8.7-10.3&#xA0;g/dL); and alkaline phosphatase, 1670 U/L (normal range: 115-359 U/L). The patient underwent renal biopsy and was diagnosed with clear cell carcinoma of the left kidney. He received 5&#xA0;mg of axitinib twice daily for 3&#xA0;months, because we thought that immediate radical surgery was not safe because of his poor performance status and laboratory data paraneoplastic syndrome. Fortunately, no serious adverse events were reported during this treatment. The patient convalesced during the administration of axitinib, and all laboratory data were restored to within normal limits after axitinib treatment. An abdominal CT after the axitinib therapy showed that the tumor diameter shrank by 56% (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>A, B). At that time, we were convinced that his renal tumor could be removed safely. Left radical nephrectomy was performed. The operation time was 95&#xA0;min, and the estimated blood loss was 50&#xA0;mL. No intraoperative or postoperative complications including wound healing delay or hemorrhage resulted from surgery. Macroscopic examination revealed a solid, yellowish-white tumor measuring 4&#x2009;&#xD7;&#x2009;2.5&#xA0;cm in size, with necrosis in the lower pole of the resected kidney (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>). Pathological examination indicated pT3aN0M0, Furman grade 3, clear cell RCC with necrosis, hyaline degeneration, and hemosiderosis (Figure&#xA0;<xref ref-type="fig" rid="F4">4</xref>). Fifty percent of tumor tissue was necrosis, and it was central necrosis. The patient was asymptomatic and disease-free at 1&#xA0;year post-diagnosis.</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Abdominal enhanced computed tomography (CT) after axitinib treatment.</bold> (<bold>A</bold>, axial section; <bold>B</bold>, coronal section). Abdominal CT shows a hypervascular tumor (size, 4.5&#x2009;&#xD7;&#x2009;2.5&#xA0;cm) in the lower pole of the left kidney. The tumor diameter shrank by 56%, compared to that before axitinib treatment.</p>
        </caption>
        <graphic xlink:href="1756-0500-6-484-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Macroscopic findings.</bold> Macroscopic examination reveals a solid tumor measuring 4&#x2009;&#xD7;&#x2009;2.5&#xA0;cm in size in the lower pole of the resected kidney (arrow).</p>
        </caption>
        <graphic xlink:href="1756-0500-6-484-3"/>
      </fig>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p><bold>Hematoxylin-eosin stained section.</bold> The pathological findings indicate clear cell renal cell carcinoma with necrosis, hyaline degeneration, and hemosiderosis (magnification: &#xD7;200).</p>
        </caption>
        <graphic xlink:href="1756-0500-6-484-4"/>
      </fig>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>To the best of our knowledge, this is the first reported case of presurgical axitinib therapy in a patient with RCC.</p>
      <p>Targeted molecular therapies such as sunitinib have changed the management of advanced or metastatic RCC. TKIs have significantly improved progression-free survival, and sunitinib, in particular, achieved a median overall survival of &gt;2&#xA0;years in advanced RCC patients [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Therefore, neoadjuvant or presurgical treatments have been suggested as treatment options for patients with advanced or unresectable RCC. Several studies suggested that targeted therapies in the neoadjuvant setting were safe, well tolerated, and did not increase surgical morbidity or perioperative complications in selected patients [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. However, these findings have been limited to small, uncontrolled, single-institution studies.</p>
      <p>Potential disadvantages of presurgical or neoadjuvant targeted therapy include the lack of optimal surgical timing after systemic therapy and the risk of increased surgical morbidity [<xref ref-type="bibr" rid="B11">11</xref>]. Recent reports have cited complications such as poor wound healing and hemorrhage [<xref ref-type="bibr" rid="B12">12</xref>]. Chapin reported that presurgical targeted therapy remained a significant predictor of wound complications in a multivariate analysis (odds ratio, 4.14; <italic>P</italic>&#x2009;=&#x2009;0.03) [<xref ref-type="bibr" rid="B13">13</xref>]. In a prospective study, the incidence of delayed superficial wound healing was higher in patients who received preoperative bevacizumab than in a historic matched cohort of 101 patients who underwent upfront surgery [<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <p>Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptor-1, 2, and 3 [<xref ref-type="bibr" rid="B15">15</xref>]. Axitinib has shown anti-tumor activity as a single agent with an acceptable safety profile in several solid tumors including previously treated metastatic RCC [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Adverse events observed in Japanese patients as well as in the overall axitinib-treated population, included diarrhea, hypertension, and fatigue [<xref ref-type="bibr" rid="B16">16</xref>]. Although axitinib was less effective for patients with poor PS [<xref ref-type="bibr" rid="B4">4</xref>], axitinib was generally well tolerated and had an acceptable safety profile in Japanese patients with metastatic RCC. Therefore, axitinib was administered for advanced RCC in this case.</p>
      <p>In conclusion, this case study indicates that presurgical targeted therapy with axitinib might have several potential advantages for patients with advanced RCC. However, the indications and clinical benefits of neoadjuvant or presurgical axitinib therapy remain to be determined. It will thus be necessary to investigate many cases in a large clinical study.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>CT: Computed tomography; RCC: Renal cell carcinoma; TKI: Tyrosine kinase inhibitor.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>TK drafted the manuscript. OA, HY, TY, and AI performed clinical follow-up examinations and contributed to the manuscript. YH viewed the pathological specimens. CO, TK, and HS performed the surgeries. CO was responsible for the concept, design, data interpretation, and critical manuscript revision. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Motzer</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Huston</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Tomczak</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Michaelson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Bukowski</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Rixe</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Oudard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Negrier</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Szczylik</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>ST</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Bycott</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Baum</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Figlin</surname>
            <given-names>RA</given-names>
          </name>
          <article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title>
          <source>N Eng J Med</source>
          <year>2007</year>
          <volume>356</volume>
          <fpage>115</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa065044</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Amin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wallen</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Pruthi</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Calvo</surname>
            <given-names>BF</given-names>
          </name>
          <name>
            <surname>Godley</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Rathmell</surname>
            <given-names>WK</given-names>
          </name>
          <article-title>Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy</article-title>
          <source>Urology</source>
          <year>2008</year>
          <volume>72</volume>
          <fpage>864</fpage>
          <lpage>868</lpage>
          <pub-id pub-id-type="doi">10.1016/j.urology.2008.01.088</pub-id>
          <pub-id pub-id-type="pmid">18684493</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kondo</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hashimoto</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kobayashi</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Iizuka</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nishikawa</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Nakano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2010</year>
          <volume>40</volume>
          <fpage>1173</fpage>
          <lpage>1179</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hyq150</pub-id>
          <pub-id pub-id-type="pmid">20696817</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rini</surname>
            <given-names>BI</given-names>
          </name>
          <name>
            <surname>Escudier</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Tomczak</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kaprin</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Szczylik</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hutson</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Michaelson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Gorbunova</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Gore</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Rusakov</surname>
            <given-names>IG</given-names>
          </name>
          <name>
            <surname>Negrier</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ou</surname>
            <given-names>YC</given-names>
          </name>
          <name>
            <surname>Castellano</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>HY</given-names>
          </name>
          <name>
            <surname>Uemura</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Tarazi</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cella</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rosbrook</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Motzer</surname>
            <given-names>RJ</given-names>
          </name>
          <article-title>Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial</article-title>
          <source>Lancet</source>
          <year>2011</year>
          <volume>378</volume>
          <fpage>1931</fpage>
          <lpage>1939</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61613-9</pub-id>
          <pub-id pub-id-type="pmid">22056247</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kawashima</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tsujimura</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Takayama</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Arai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Nin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tanigawa</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Yasunaga</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Mukai</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Uemura</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nakai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Nishimura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nonomura</surname>
            <given-names>N</given-names>
          </name>
          <collab>Osaka Renal Cell Carcinoma Clinical Study Collaboration</collab>
          <article-title>Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma</article-title>
          <source>Med Oncol</source>
          <year>2012</year>
          <volume>29</volume>
          <fpage>3298</fpage>
          <lpage>3305</lpage>
          <pub-id pub-id-type="doi">10.1007/s12032-012-0236-6</pub-id>
          <pub-id pub-id-type="pmid">22544539</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fruehauf</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lutzky</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>McDermott</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>CK</given-names>
          </name>
          <name>
            <surname>Meric</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Rosbrook</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Shalinsky</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Liau</surname>
            <given-names>KF</given-names>
          </name>
          <name>
            <surname>Niethammer</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rixe</surname>
            <given-names>O</given-names>
          </name>
          <article-title>Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>7462</fpage>
          <lpage>7469</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0534</pub-id>
          <pub-id pub-id-type="pmid">21976544</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="book">
          <name>
            <surname>Sobin</surname>
            <given-names>LH</given-names>
          </name>
          <source>TNM Classification of Malignant Tumors</source>
          <year>2002</year>
          <publisher-name>New York: Wiley-Liss</publisher-name>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Escudier</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Eisen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Stadler</surname>
            <given-names>WM</given-names>
          </name>
          <name>
            <surname>Szczylik</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Oudard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Siebels</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Negrier</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chevreau</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Solska</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Desai</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Rolland</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Demkow</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hutson</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Gore</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Freeman</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Shan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Simantov</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bukowski</surname>
            <given-names>RM</given-names>
          </name>
          <collab>TARGET Study Group</collab>
          <article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title>
          <source>N Eng J Med</source>
          <year>2007</year>
          <volume>356</volume>
          <fpage>125</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa060655</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Motzer</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Huston</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Tomezak</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Michaelson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Bukowski</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Oudard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Negrier</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Szczylik</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Pili</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bjarnason</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Garcia-del-Muro</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Sosman</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Solska</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Wilding</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>ST</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Figlin</surname>
            <given-names>RA</given-names>
          </name>
          <article-title>Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>3584</fpage>
          <lpage>3590</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2008.20.1293</pub-id>
          <pub-id pub-id-type="pmid">19487381</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Thomas</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Rini</surname>
            <given-names>BI</given-names>
          </name>
          <name>
            <surname>Stephenson</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Garcia</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Fergany</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Krishnamurthi</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Novick</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Gill</surname>
            <given-names>IS</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>AC</given-names>
          </name>
          <article-title>Surgical resection of renal cell carcinoma after targeted therapy</article-title>
          <source>J Urol</source>
          <year>2009</year>
          <volume>182</volume>
          <fpage>881</fpage>
          <lpage>886</lpage>
          <pub-id pub-id-type="doi">10.1016/j.juro.2009.05.014</pub-id>
          <pub-id pub-id-type="pmid">19616232</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ficarra</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Novara</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Neoadjuvant targeted therapies in renal cell carcinoma</article-title>
          <source>Nat Rev Urol</source>
          <year>2010</year>
          <volume>7</volume>
          <fpage>63</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1038/nrurol.2010.2</pub-id>
          <pub-id pub-id-type="pmid">20145660</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Harshman</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Allen</surname>
            <given-names>GI</given-names>
          </name>
          <name>
            <surname>Srinivas</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gill</surname>
            <given-names>HS</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>BI</given-names>
          </name>
          <article-title>Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)</article-title>
          <source>Urol Oncol</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>379</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="doi">10.1016/j.urolonc.2011.01.005</pub-id>
          <pub-id pub-id-type="pmid">21353796</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chapin</surname>
            <given-names>BF</given-names>
          </name>
          <name>
            <surname>Delacroix</surname>
            <given-names>SE</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Culp</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Nogueras Gonzalez</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Tannir</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Jonasch</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Tamboli</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wood</surname>
            <given-names>CG</given-names>
          </name>
          <article-title>Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma</article-title>
          <source>Eur Urol</source>
          <year>2011</year>
          <volume>60</volume>
          <fpage>964</fpage>
          <lpage>971</lpage>
          <pub-id pub-id-type="doi">10.1016/j.eururo.2011.05.032</pub-id>
          <pub-id pub-id-type="pmid">21621907</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jonasch</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Wood</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Matin</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Tu</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Pagliaro</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Corn</surname>
            <given-names>PG</given-names>
          </name>
          <name>
            <surname>Aparicio</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tamboli</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Millikan</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Araujo</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Arap</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Tannir</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>4076</fpage>
          <lpage>4081</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2008.21.3660</pub-id>
          <pub-id pub-id-type="pmid">19636008</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Goldstein</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Pickering</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Larkin</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?</article-title>
          <source>Expert Rev Anticancer Ther</source>
          <year>2010</year>
          <volume>10</volume>
          <fpage>1545</fpage>
          <lpage>1557</lpage>
          <pub-id pub-id-type="doi">10.1586/era.10.134</pub-id>
          <pub-id pub-id-type="pmid">20942625</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ueda</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Uemura</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Tomita</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tsukamoto</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kanayama</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shinohara</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Tarazi</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ozono</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Naito</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Akaza</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2013</year>
          <volume>43</volume>
          <fpage>616</fpage>
          <lpage>628</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hyt054</pub-id>
          <pub-id pub-id-type="pmid">23630366</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
